Cue Biopharma (NASDAQ:CUE) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Cue Biopharma (NASDAQ:CUE) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings raised Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cue Biopharma presently has a consensus rating of “Sell”.

Cue Biopharma Stock Performance

Shares of NASDAQ CUE opened at $34.20 on Friday. The company’s fifty day moving average price is $29.50 and its 200 day moving average price is $147.28. The company has a market capitalization of $143.64 million, a PE ratio of -1.27 and a beta of 2.47. Cue Biopharma has a 1 year low of $4.97 and a 1 year high of $45.50.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The company had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.

Insider Buying and Selling

In related news, CEO Shao-Lee Lin sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00. Following the sale, the chief executive officer directly owned 724,253 shares in the company, valued at approximately $19,627,256.30. This represents a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 14.56% of the stock is owned by insiders.

Institutional Investors Weigh In On Cue Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC purchased a new stake in shares of Cue Biopharma during the 2nd quarter worth $1,742,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Cue Biopharma in the second quarter valued at $83,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Cue Biopharma during the 2nd quarter worth about $722,000. BlackRock Inc. purchased a new stake in Cue Biopharma during the 2nd quarter worth about $1,824,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Cue Biopharma during the 2nd quarter worth about $389,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Key Cue Biopharma News

Here are the key news stories impacting Cue Biopharma this week:

• Positive Sentiment: Second-quarter 2026 revenue was $7.88 million, well above analysts’ $3.00 million estimate. The company also reported recent business highlights, providing potentially supportive news for its clinical-stage immunotherapy pipeline. Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Neutral Sentiment: Institutional ownership stands at approximately 35.04%, with several funds increasing their positions in recent quarters. This suggests some investor interest, although the reported holdings are relatively small compared with the company’s market capitalization.
• Neutral Sentiment: CEO Shao-Lee Lin sold a combined 58,258 shares for about $1.61 million across August 12 and 13. The filings state that the sales were intended to cover tax-withholding obligations related to vested equity awards, reducing the significance of the transactions as a discretionary bearish signal. Lin still owned 705,995 shares after the latest sale. Cue Biopharma CEO Sells Stock
• Negative Sentiment: Cue Biopharma reported a quarterly loss of $24.14 per share, far worse than the consensus estimate of a $1.69 loss. The company also posted a negative net margin of 59.65% and negative return on equity of 98.30%, highlighting ongoing profitability and potential financing risks.
• Negative Sentiment: Wall Street Zen downgraded CUE from “Buy” to “Hold.” MarketBeat said the broader analyst consensus remains “Sell,” with one tracked analyst carrying a Sell rating. Wall Street Zen Downgrades Cue Biopharma

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.